Total revenue growth of 16%; Software revenue growth of 19%; Diluted Earnings Per Share (EPS) growth of 25%
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close... January 6, 2022.
Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1
Update includes enhanced PKanalix, Monolix, and Simulx modules
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
Conference Call to be on Thursday, January 6, 2022, at 5:00 PM ET
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
Complementing the existing distributorship with ADMET Predictor® and GastroPlus® software
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope
Expanding access to high-quality medication for people in need
Simulations Plus Names Sharlene Evans to Board of Directors
Experienced Human Resource, Development and Organizational Leader Bolsters Board
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference
Yo-Yo dieting without additional treatment can explain high placebo response rates in NASH clinical trials
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
New RENAsym platform helps drug developers avoid kidney injury side effects
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym...
Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products
Collaboration will combine novel experimental techniques and mechanistic modeling strategies
Simulations Plus Reports Fourth Quarter and Full Year Fiscal 2021 Results
Fiscal 2021 revenue increased 12% year-over-year to $46.5 million
Software revenue increased 28% year-over-year to $27.7 million
Fiscal 2022 financial outlook for total revenue of $51 million to $53 million, reflecting 10% to 15% year-over-year growth
Simulations Plus Announces the University+ Program
Free access to Simulations Plus software for accredited universities will accelerate learning and educational pursuits
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call
Conference Call to be on Monday, October 25, 2021, at 5:00 PM ET
Simulations Plus Receives New Grant Award From the FDA
Improvements to the GastroPlus® platform will increase its impact in driving research and regulatory decisions on dermatological products
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be...
Simulations Plus Reports Continued Success in Second Phase of AIDD Collaboration with Large Pharmaceutical Company
30% of synthesized molecules have measured activity which meet potency targets.
NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®
Simulations Plus announced that China's Center for Drug Evaluation of the NMPA has added GastroPlus licenses for research aiding regulatory reviews